Hans Hull News Today

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $48.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 190.56% from the company’s previous close. A […]

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]

Rhenman & Partners Asset Management AB acquired a new stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 330,635 shares of the company’s stock, valued at approximately $5,733,000. Rhenman & Partners Asset Management AB […]

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report)’s stock price reached a new 52-week low on Wednesday . The stock traded as low as $14.12 and last traded at $14.15, with a volume of 14016 shares trading hands. The stock had previously closed at $14.78. Analyst Ratings Changes Several equities analysts recently issued reports on […]

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $50.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 199.22% from the company’s previous close. PLRX has been the […]

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been assigned an average rating of “Buy” from the eleven brokerages that are presently covering the firm, Marketbeat reports. Eleven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issued a report on the […]

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) shares fell 5.1% during mid-day trading on Wednesday . The company traded as low as $17.01 and last traded at $17.02. 144,557 shares changed hands during trading, a decline of 83% from the average session volume of 844,613 shares. The stock had previously closed at $17.93. Analyst […]

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.03, reports. Pliant Therapeutics had a negative net margin of 2,872.79% and a negative return on equity of 33.10%. The company had revenue of $0.25 million during […]

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They presently have a $45.00 target price on the stock. Needham & Company LLC’s price target indicates a potential upside of 149.58% from the company’s […]